China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
559 Views
Unique biopharmaceutical company with high barrier of entry, high growth expected, take the deal
3SBio is a leading biopharmaceutical company based in China offering products including EPIAO to cure anemia in Chronic Kidney Disease (CKD),...
364 Views
A Leading Chinese Biotech Company, Quality Cornerstones, Take the Deal
3SBio, a leading Chinese biotechnology company, plans to re-list in Hong Kong after de-listing from NASDAQ in 2013. The company's two main...
399 Views
Opening of E-commerce Channel to Change China's Drug Market
Numerous press outlets report that China’s Food & Drug Administration (CFDA) will release regulations permitting online sales of...
519 Views
Introducing Long Term Leaders - Focussed Insights for your Core Holdings
We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...
439 Views